Viyash Scientific

    VIYASH
    Pharma
    ₹235.61
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹10,404 Cr

    P/E
    57.61
    Day range
    ₹228.81 – ₹237.11
    52-week range
    ₹178.13 – ₹298.00
    Volume
    22.16 L
    Open
    ₹235.80
    Prev close
    ₹237.40

    Latest results · Q2 FY27(consolidated)Revenue ₹988 Cr+133.0%Profit ₹85 Cr+331.9%Margin 8.6%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      49.24%, down 12.19 pts since 2025-12-16 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 48 / 100

    Factor percentiles

    Value47
    Quality53
    Momentum53
    Low volatility37

    Derived metrics

    Earn. yield
    1.7%
    Graham no.
    ₹93.58
    vs Graham
    -60.3%
    ROE ÷ P/B
    2.5%
    Magic Formula
    #515
    Piotroski
    6/6
    FCF yield
    1.8%
    PEG
    0.11

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Viyash ScientificVIYASH₹10,404 Cr57.613.318.4%13.0%17.0%0.18+16.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 4h ago

    Headlines about Viyash Scientific from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    43.4
    Price / Book
    3.29
    ROE (FY26)
    8.4%
    ROCE (latest year)
    13%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹227.18
    Price above
    50-day
    ₹237.56
    Price below
    200-day
    ₹235.62
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +34.0%
    Revenue YoY (Sep 2026)
    +16.2%
    Profit YoY (Sep 2026)
    +16.4%
    Operating margin
    17.0%
    Net margin
    8.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr250 Cr500 Cr750 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%10%20%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-600 Cr-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-20%0%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY20FY21FY22₹0₹0.2₹0.4₹0.6

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales329361390369774402792850858920946988
    YoY Sales growth-12-1——————————
    Expenses307329348330674355673677683736768823
    Operating Profit2232423910046119173176184178165
    OPM %7%9%11%11%13%12%15%20%20%20%19%17%
    Other Income7-1304166-2716812
    Interest131216142115201817151314
    Depreciation151616175816565959606245
    Profit before tax1312824164810273125112118
    Tax %-617%52%24%20%-71%36%24%29%34%47%29%28%
    Net Profit111964210377349667985
    EPS in Rs₹0.33₹-0.04₹0.26₹0.10₹1.78₹0.37₹1.27₹2.18₹0.88₹1.19₹1.51₹1.72

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days112

    +19 days since Mar 2021

    Inventory Days188

    +49 days since Mar 2021

    Days Payable140

    +21 days since Mar 2021

    Cash Conversion Cycle160

    +48 days since Mar 2021

    Working Capital Days111

    +60 days since Mar 2021

    Strengths, risks & growth

    Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

    Strengths

    • Company is expected to give good quarter

    Risks

    • Stock is trading at 3.31 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Promoter holding has decreased over last quarter: -12.1%
    • Company has a low return on equity of 3.80% over last 3 years.
    • Working capital days have increased from 71.6 days to 111 days

    Compounded Sales Growth

    10 Years
    +19%
    5 Years
    +20%
    3 Years
    +34%
    TTM
    +32%

    Compounded Profit Growth

    10 Years
    +28%
    5 Years
    +15%
    3 Years
    +73%
    TTM
    +70%

    Stock Price CAGR

    10 Years
    +8%
    5 Years
    +6%
    3 Years
    +34%
    1 Year
    +3%

    Return on Equity

    10 Years
    +8%
    5 Years
    +3%
    3 Years
    +4%
    Last Year
    +7%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter61.41%61.31%61.31%49.24%-12.07 pp
    FII3.16%2.94%4.50%2.60%-1.90 pp
    DII7.36%7.98%3.76%8.30%+4.54 pp
    Public27.97%27.67%30.34%39.76%+9.42 pp
    Others0.09%0.09%0.09%0.09%0.00 pp

    Filed with NSE for Sept 2026: promoters 49.24%, public 50.66%

    Risk & trend

    From 200 daily sessions to 17 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    43.8%
    Downside volatility
    39.8%
    Worst 5% of days
    4.5%
    Average of that tail
    5.6%
    Max drawdown (1Y)
    30.6%
    Below its peak
    19.3%

    Against the market

    Beta vs Nifty 50
    1.19
    Correlation
    0.42
    Relative strength (3M)
    -11.3%
    ATR (14)
    4.6%

    Return

    Return 1M
    +5.1%
    Return 3M
    -7.1%
    Return 6M
    +5.7%
    Return 1Y
    —
    vs 200-day average
    +0.8%

    Momentum

    RSI (14)
    52.0
    MACD histogram
    2.95
    Stochastic %K
    53.5
    ADX (14)
    19.0
    +DI / −DI
    25.9 / 22.1
    Money flow index
    66.3

    Participation

    Delivery (20d avg)
    49.0%
    vs its 60-day baseline
    -2.4 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    -0.4%
    52-week position
    50 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹188 Cr
    FCF yield
    1.8%
    Cash conversion
    2.12
    Accruals ratio
    -0.037
    Net debt
    ₹234 Cr
    Net debt / equity
    0.08
    EV / sales
    2.89
    PEG
    0.11
    Capex intensity
    5.1%
    Revenue CAGR
    129.0%
    Profit CAGR
    539.5%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share

      8 Sept 2021
      ex-date
    • dividend
      ₹0.20

      Annual General Meeting/Dividend - Rs 0.20 Per Share

      21 Aug 2019
      ex-date
    • other
      Not available — not reported in this filing

      Scheme Of Arrangement

      6 Apr 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.20 Per Share

      20 Nov 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      15 Sept 2016
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of ESOP

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Re. 74(5) of SEBI (DP) Regulation is enclosed.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Updates on Acquisition

    Completion of acquisition of BioForLife Italia S.r.l.

    Insider Trading / SAST
    Closure of Trading Window

    Closure of Trading Window for Q2 FY 2026-27

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of ESOP

    Company Update
    Update On Proposed Acquisition Of Bioforlife Italia S.R.L

    Update on proposed acquisition of BioForLife Italia S.r.l

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of ESOP

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Harbor Investment & CA Hull Investments

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Earning call Transcript Q1 FY 2026-27

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Recording of Earnings call pertaining to the unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication for Financial Results of Q1 FY 27.

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation Q1 FY 2026-2027

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results and scrutinizer Report

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results and scrutinizer Report

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of the 41st AGM held on August 11, 2026

    Filed with BSE (scrip 512529); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Viyash Scientific: common questions

    Answered from the figures on this page.

    Viyash Scientific last traded at ₹235.61 (NSE, as of 18 Nov 2026). The last session moved it down 0.75%.

    Viyash Scientific is valued at about ₹10,404 crore (NSE, as of 18 Nov 2026).

    Viyash Scientific trades at a price-to-earnings ratio of 57.61 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Viyash Scientific has traded between ₹178.13 and ₹298.00 over the past 52 weeks, to 18 Nov 2026. It is currently 48% of the way up that range.

    Viyash Scientific (VIYASH) is classified under Pharma on this site's screener.